A SAD/MAD Study to Evaluate the Safety, Tolerability, PK and PD of MT2004

Exclusion Criteria

• •1. Clinically significant history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, or drug hypersensitivity as determined by the Investigator;
• •2. Known or suspected malignancy;
• •3. History of pancreatitis or gall stones;
• •4. History of unexplained syncope, symptomatic hypotension or hypoglycemia;
• •5. Family history of long QTc syndrome;
• •6. History of chronic diarrhea, malabsorption, unexplained weight loss, food allergies or intolerance;
• •7. History of organ transplantation with the exception of cornea transplantation;
• •8. Poor venous access;
• •9. Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibody;
• •10. Donated or lost \>500ml of blood in the previous 3 months;
• •11. Taken an investigational drug or participated in a clinical trial within 3 months (or 5 half- lives), whichever is longer;
• •12. Taken any prescription medications within 14 days or 5 half-lives (whichever is longer) of the first dose of study drug;
• •13. Hospital admission or major surgery within 6 months prior to screening;
• •14. A history of prescription drug abuse, or illicit drug use within 9 months prior to screening;
• •15. A history of alcohol abuse according to medical history within 9 months prior to screening;
• •16. A positive screen for alcohol and/or drugs of abuse at screening or Day
• •-1;
• •17. An unwillingness or inability to comply with food and beverage restrictions during study participation;
• •18. Use of over-the-counter (OTC) medication within 7 days, and herbal (including St John's Wort, herbal teas, garlic extracts) within 7 days prior to dosing (Note: Use of acetaminophen at \< 2 g/day is permitted until 24 hours prior to dosing);
• •19. Pregnant or breast feeding at screening or planning to become pregnant during the study;
• •20. Inability to swallow multiple capsules simultaneously
• •21. Any condition or finding that in the Investigators opinion would put the subject or study conduct at risk if the subject were to participate in the study.